1. Two-Year Outcomes After Everolimus- or Sirolimus-Eluting Stents in Patients With Coronary Artery Diseasein the ISAR-TEST 4 Trial Robert A. Byrne, Adnan Kastrati, Klaus Tiroch, Steffen Massberg, Anna Wieczorek, Karl-Ludwig Laugwitz, Stefanie Schulz, Jürgen Pache, Massimiliano Fusaro, Melchior Seyfarth, Albert Schömig, Julinda Mehilli Deutsches Herzzentrum & 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich. Germany

2. Presenter Disclosure Information: Nothing to disclose

3. Intracoronary Stenting and Angiographic Results:Test Efficacy of 3 Limus-Eluting Stents - 4 2603 patients with de novo lesions Biodegradable polymer DES (BP-DES) n=1299 Permanent polymer DES (PP-DES:Xience & Cypher) n=1304 6-8 month & 2 year FU angiography 24-month clinical follow-up ISAR-TEST 4 Study Algorithm Byrne et al. Eur Heart J 2009

6. 100 RR 0.85 [95% CI, 0.65-1.11], P=0.23 % 80 60 40 Sirolimus-eluting stent, 18.8% 20 Everolimus-eluting stent, 16.0% 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Months after randomization Cardiac Death, Target Vessel MI, TLR

7. 5 RR 0.75 [95% CI, 0.32-1.78], P=0.52 % 4 3 Sirolimus-eluting stent, 1.9% 2 Everolimus-eluting stent, 1.4% 1 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Months after randomization Definite or Probable Stent Thrombosis

8. Definite Stent Thrombosis EES (0.6%) P=0.17 SES (1.4%)

9. 100 RR 0.73 [95% CI, 0.52-1.01], P=0.06 % 80 60 40 Sirolimus-eluting stent, 13.5% 20 Everolimus-eluting stent, 9.9% 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Months after randomization Target Lesion Revascularization

11. While there was a trend towards superior antirestenotic efficacy with Xience EES, specifically-powered studies are needed to evaluate the clinical significance of this findingConclusions

12. ISAR-TEST-4Deutsches Herzzentrum, Munich. Germany Thank You